Skip to NavigationSkip to content

Mylan buys into women’s health

Published on 03/02/15 at 03:02pm
Mylan image

Mylan is to acquire a number of women’s healthcare companies from Indian-based Famy Care that will build upon its 2008 partnership to create a franchise in developing countries.

The $750 million transaction is expected to close in the second half of 2015 and comes less than a year after US-based Mylan purchased Abbott's branded generics business, which also includes a women's healthcare portfolio.

The partnership already offers a portfolio of 12 approved products, plus impending US Food and Drugs Administration applications for 30 more.

“We foresee significant opportunities in the women's healthcare business across developed and emerging markets, and the proposed transaction provides an opportunity for our team to capture the opportunity in an even more effective manner,” comments JP Taparia, who is the non-executive chairman of Famy Care.

Famy Care is a female healthcare specialist that manufactures a range of women’s fertility-control products including oral and injectable contraceptives, intra-uterine devices (IUDs) and tubal rings ­– along with hormone-replacement therapy goods.

Famy Care is the first generics company to have received pre-qualification from the World Health Organization for hormonal contraceptives, and according to the firm more than 15% of the world's female population on oral birth-control pills use a Famy Care product.

Mylan’s chief executive Heather Bresch says: “In 2008, Mylan established a partnership with Famy Care, significantly enhancing its presence in the women's healthcare segment in the US and other developed country markets. With today's acquisition, we are building on this successful partnership and further accelerating our global growth in this important therapeutic area.”

According to research company Business Insights (BI), the women's healthcare market is growing at an annual rate of approximately 6%, with hormonal contraceptives representing the largest and fastest growing products in the segment.

BI’s research also states that emerging markets represent an important growth opportunity for the sector. The deal is supported by global initiatives, such as Family Planning 2020 – which provides funding for fertility-control medicine in these markets.

Commenting on what it means for Mylan’s business outlook, the firm’s president Rajiv Malik concludes: “In addition to the opportunities we see in North America and Europe, Famy Care's businesses will strengthen our position in emerging markets. We see opportunities for generating more front-end sales, in addition to Famy Care's successful partnering strategy.”

Tom Robinson

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches